Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

Evidence-based clinical practice guidelines for peptic ulcer disease 2020

(2021) Tomoari Kamada et al.   JOURNAL OF GASTROENTEROLOGY

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

(2021) Theodore Rokkas et al.   GASTROENTEROLOGY

The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis

(2021) Juan Fu et al.   PHARMACOGENOMICS

Clinical audit of current Helicobacter pylori treatment outcomes in Singapore

(2021) TL Ang et al.   SINGAPORE MEDICAL JOURNAL

Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg)

(2021) Luis Bujanda et al.   Antibiotics-Basel

Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori

(2021) Chalermrat Bunchorntavakul et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis

(2021) Yuko Morino et al.   Frontiers in Pharmacology

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

(2020) Sho Suzuki et al.   GUT

Tu1362 2-YEAR INTERIM ANALYSIS RESULTS OF VISION TRIAL: A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF VONOPRAZAN AS MAINTENANCE TREATMENT IN PATIENTS WITH EROSIVE ESOPHAGITIS

(2020) Naomi Uemura et al.   GASTROENTEROLOGY

Recent Developments Pertaining to H. pylori Infection

(2020) Colin W. Howden et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

(2019) Mototsugu Kato et al.   HELICOBACTER

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

(2018) Kiyoshi Ashida et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis

(2017) James K.Y. Hooi et al.   GASTROENTEROLOGY

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

(2017) Shou Quan Dong et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

(2016) Hiroshi Matsumoto et al.   DIGESTIVE DISEASES AND SCIENCES

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori

(2016)   Journal of Gastrointestinal and Liver Diseases

CYP2C19 polymorphism influencesHelicobacter pylorieradication

(2016) Chao-Hung Kuo et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Ten-day triple therapyversussequential therapyversusconcomitant therapy as first-line treatment forHelicobacter pyloriinfection

(2015) Tiing Leong Ang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

(2015) Richard H Hunt et al.   Clinical and Translational Gastroenterology

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region With High Rates of Multiple Drug Resistance

(2014) Chung-Su Park et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association of Helicobacter pylori dupA With the Failure of Primary Eradication

(2012) Seiji Shiota et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection

(2010) Takahisa Furuta et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy

(2009) Mitsushige Sugimoto et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology